Bayer soars on promising trial results for stroke prevention drug
Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges
Related reading
Europe’s pharma industry risks lagging behind US and China, says German…
Boehringer Ingelheim says pricing regime hinders access to treatments as group touts liver benefits from weight-loss drug
Novo Nordisk shares slump after drug failure in Alzheimer’s trial
Outcome is blow to one of Europe’s largest listed companies
Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda
Merck’s record cancer drug sales power earnings growth
Quarterly proceeds from Keytruda top $8bn for first time
Bayer’s ambitions boosted by relaxation of EU gene-edited crop rules
German life sciences giant says looser regulations could reshape Europe’s €6bn seed market
US set to speed up approval for some generic drugs in blow to Big Pharma
Move is latest broadside by Trump administration against pharmaceuticals industry that fought to derail changes